HomeSOBI • STO
add
Swedish Orphan Biovitrum AB (publ)
Previous close
kr 326.20
Day range
kr 325.40 - kr 330.00
Year range
kr 206.20 - kr 338.20
Market cap
116.84B SEK
Avg Volume
393.65K
P/E ratio
53.33
Dividend yield
-
Primary exchange
STO
Financials
Income Statement
Revenue
Net income
| (SEK) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 5.44B | 11.70% |
Operating expense | 3.52B | 24.61% |
Net income | 224.00M | 0.90% |
Net profit margin | 4.12 | -9.65% |
Earnings per share | 0.72 | -51.02% |
EBITDA | 1.56B | 21.06% |
Effective tax rate | 18.55% | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 779.00M | -1.39% |
Total assets | 73.17B | -3.45% |
Total liabilities | 36.82B | -22.34% |
Total equity | 36.35B | — |
Shares outstanding | 342.53M | — |
Price to book | 3.08 | — |
Return on assets | 2.18% | — |
Return on capital | 2.96% | — |
Cash Flow
Net change in cash
| (SEK) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | 224.00M | 0.90% |
Cash from operations | 2.33B | 552.38% |
Cash from investing | -44.00M | 99.75% |
Cash from financing | -2.04B | -111.36% |
Net change in cash | 252.00M | -57.43% |
Free cash flow | 2.24B | 403.56% |
About
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees. Wikipedia
Founded
1939
Website
Employees
1,772
